PARP7-IN-16 free base

Cat. No.: HY-156419A

CAS No.: 2136325-05-6

Molecular Formula: $C_{25}H_{27}FN_4O_4$

Molecular Weight: 466.5

Target: PARP

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (71.45 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1436 mL	10.7181 mL	21.4362 mL
	5 mM	0.4287 mL	2.1436 mL	4.2872 mL
	10 mM	0.2144 mL	1.0718 mL	2.1436 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PARP7-IN-16 free base is the free base form of PARP7-IN-16 (HY-156419). PARP7-IN-16 free base is a selective and orally active inhibitor of PARP-1/2/7, with IC_{50}s of 0.94, 0.87 and 0.21 nM, respectively. PARP7-IN-16 can be used for the research of breast cancer and prostate cancer[1].

IC_{50} & Target

PARP7	PARP2	PARP1
0.21 nM (IC_{50})	0.87 nM (IC_{50})	0.94 nM (IC_{50})

REFERENCES

[1]. Zhou J, et, al. Discovery of Quinazoline-2,4(1 H,3 H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors：Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. J Med Chem. 2023 Oct 26;66(20):14095-14115.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA